emperor-preserved-heart-failure-toplineresults emperor-preserved-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
emperor-preserved-kidney-subanalysis emperor-preserved-kidney-subanalysis New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY trial early stop due to positive efficacy EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy